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SUPPLEMENTARY NOTES
ABSTRACT
This project aims to gain a better understanding of the implications of genetic testing for breast-ovarian cancer susceptibility. The primary goal is to evaluate the impact of BRCA1/BRCA2 mutation testing on long term psychosocial (quality of life, distress, social functioning) and prevention/surveillance (mammography, CA125, transvaginal ultrasound, prophylactic mastectomy, prophylactic oophorectomy and chemoprevention) outcomes. To accomplish this we will measure outcomes within a group of women who received BRCA1/BRCA2 test results at least four years ago. We will divide our sample based upon their personal cancer history -evaluating cancer survivors with different measures compared to unaffected individuals. For both survivors and unaffected individuals we will recruit separate comparison samples of women who have never received BRCA1/BRCA2 testing.
SUBJECT TERMS
BRCA1, BRCA2, Outcomes
INTRODUCTION
Genetic testing for breast-ovarian cancer susceptibility has the potential to reduce breast and ovarian cancer mortality among high risk women. However, there has been ongoing concern regarding the quality of life implications of learning one's mutation status. One of the main potential benefits of BRCA1/BRCA2 testing is to motivate carriers to take behavioral action to reduce their risk of breast and ovarian cancer mortality. However, we do not yet know whether carriers actually engage in such actions. Preliminary evidence suggests that a relatively small proportion of carriers obtain prophylactic surgery in the year following testing. The proportion of carriers who utilize chemopreventive agents such as tamoxifen remains unknown. The few studies to examine screening utilization in the year following disclosure found sub-optimal rates of screening among positives. In fact, rates of mammography have not been found to increase following a positive mutation test. Although mutation carriers did report higher rates of mammography, this difference was due to appropriate decreases in screening among younger noncarriers. In terms of ovarian cancer screening, rates of CA-125 and transvaginal ultrasound do increase among carriers in the year following testing. However, overall ovarian cancer screening rates remain below 30%. To date, there have been no studies to evaluate the long-term cancer prevention and screening behaviors of this population. If genetic testing is to fulfill its promise of reducing mortality among individuals from hereditary cancer families, behavioral change must follow the receipt of a positive test result. The first step to addressing this question is to evaluate the behavior of individuals in the years following testing. If individuals remain non-adherent to prevention and screening guidelines, it is particularly important to understand why and to identify early predictors of behavioral non-adherence in this vulnerable population. We will evaluate the role of distress/quality of life as a potential predictor of adverse behavioral outcomes.
The primary goal of this project is to evaluate long term psychosocial (quality of life, distress, social functioning) and prevention/surveillance (mammography, CA-125, transvaginal ultrasound, prophylactic mastectomy, prophylactic oophorectomy and chemoprevention) outcomes. To accomplish this we will measure outcomes within a group of women who received BRCA1/BRCA2 test results at least four years ago. We will divide our sample based upon their personal cancer history -evaluating cancer survivors with different measures compared to unaffected individuals. For both survivors and unaffected individuals we will recruit separate comparison samples of women who have never received BRCA1/BRCA2 testing.
Until we better understand the long-term outcomes of BRCA1/2 testing, it is unlikely that such testing will fulfill its promise to reduce breast and ovarian cancer mortality. By evaluating the impact of testing, appropriate intervention strategies can be developed so that individuals at-risk for distress or non-adherence could be targeted for early intervention and/or ongoing support. This research could provide information necessary to make decisions about how and where to allocate scarce counseling resources and to tailor health promotion efforts to individual needs. Genetic testing for breast-ovarian cancer susceptibility is becoming more widely available to the general population. Prior to its routine use, we should make sure that we fully understand its long-term implications. We are currently preparing a manuscript describing psychosocial and quality of life outcomes. The results stratified by test result group are displayed in Figures 1 and 2 . As seen in these figures, there were no differences in distress or quality of life by test result (p>.10) except for brothers; carriers were more likely to disclose their test results to their brothers than were uninformatives, X 2 (1) = 8.14, p = .004. Finally, the potential association between kinship and disclosure was examined via point-biserial correlations, with and without the potential impact of test results partialled out. These results, shown in Table 2 , consistently indicate that women who reported stronger kinship ties and closer relationships with their adult relatives during the time they underwent BRCA1/2 testing were more likely to inform those relatives of their results. The strength of these associations remained largely unchanged when genetic test results were accounted for. For children under the age of 18 years, closeness was not associated with disclosure.
BODY
We have submitted a second manuscript which evaluates risk management outcomes within this sample. This manuscript is based on an abstract presented at the annual meeting of the American Society of Preventive Oncology 1 . For this manuscript we assessed the long-term rates and predictors of Risk Reducing Mastectomy (RRM) and Risk Reducing Oophorectomy (RRO). Participants were women with >10% probability of carrying a BRCA1/2 mutation who received genetic testing 4-8 years earlier. For RRM analyses, women (n=454) had no history of breast cancer or had unilateral breast cancer. For RRO analyses, women (N=486) had no history of ovarian cancer. Women completed assessments before and 4-8 years (M=5.3 yrs) after testing.
Among women without bilateral mastectomy before testing (13% had prior bilateral mastectomy), 38% with positive test results ultimately had RRM. Among women without oophorectomy before testing (19% had prior oophorectomy), 64% of positives ultimately had RRO. Most women opting for RRM did so within one year of testing (72%), while only 39% of those with RRO had it within a year. RRM was strongly predicted by positive test result (χ 2 (df=2; N=393) = 69.3, p<.001). Among mutation carriers, those most likely to opt for RRM had a stronger family history (OR=3.5, 95% CI = 1.42-8.73) and were more anxious prior to genetic testing (OR=1.55, 95% CI = 1.04, 2.32). RRO was also strongly predicted by test result (χ 2 (df=2; N=390) = 105.2, p<.001). Among carriers, RRO was predicted only by age. Specifically, carriers age 40 or above were more than 8-fold more likely to opt for RRO (OR=8.5, 95% CI=3.2-22.0). At follow-up, women with RRM or RRO did not differ from women without surgery on quality of life or distress. Risk reducing surgery is being appropriately utilized by women at the highest risk of HBOC and does not appear to adversely impact long-term psychological outcomes.
In another abstract we evaluated the long term outcomes among BRCA1/BRCA2 uninformatives 2 . In terms of surveillance for breast cancer, most women had a mammogram (84%) and a clinical breast exam (94%) within the past year. Of the women with no prior history of ovarian cancer, 12% (n=26) reported RRO prior to receipt of test results, 10.1% (n=22) reported RRO after receipt of test results, and 77.9% (n=169) reported never having RRO. RRO was obtained an average of 2.75 years after receipt of test results (range 0.1 to 5.0 yrs). The RRO groups (never, prior, and after testing) did not differ on long-term quality of life outcomes (p<.41); however, the groups significantly differed on global distress (F=4.96, p<.01), with women who had RRO after testing reporting more distress than women who had RRO before testing. Regardless of RRO status, greater long term cancer-specific distress among uninformatives was predicted by greater levels of baseline cancer-specific distress prior to receipt of test result (β=.30, p<.001), higher current perceived risk of cancer (β= .23, p<.01), and ovarian cancer family history, specifically a greater number of relatives affected by ovarian cancer (β= .22, p<.01). A trend was found where RRO timing and status (never, prior to testing, after testing) was associated with current cancer-specific distress (β= -.15, p=.07), with BPO after receipt of uninformative results marginally related to higher current levels of cancer-specific distress.
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